Prognosis

Prognosis refers to the ability to predict how a disease will evolve in an individual person, including the chances of recovery, survival, and quality of life. Today, survival rates are around 80% for Hodgkin lymphoma and approximately 60% for non-Hodgkin lymphomas, although these figures can vary widely.

As with many cancers, prognosis in lymphoma depends on several factors. These include how aggressive the disease is, how far it has spread, and the patient’s overall health. Age, previous illnesses, and other medical conditions all play an important role. Equally important is the patient’s ability to tolerate treatment, which can sometimes be intensive.

Two key elements help define the severity of lymphoma:

• the specific subtype of lymphoma
• the extent of disease spread in the body

In general, the more widespread the disease, the greater the number of lymphoma cells and the more complex treatment may be. For this reason, it is important to assess how many lymph node areas are involved and whether other organs are affected.

Does Early Diagnosis Affect Prognosis?

A common question is how much early diagnosis influences prognosis.

Unlike many other cancers, lymphoma may develop without clear symptoms for a long time, or symptoms may appear only at a later stage. As a result, some patients are diagnosed when the disease is already advanced (stage IV).

While it is always important not to delay medical evaluation, early diagnosis plays a less decisive role in lymphoma compared to other cancers. This is because lymphomas are not like solid tumors: they are typically systemic diseases, they can involve multiple areas of the body from the outset.

Currently, there are no screening tests for early detection of lymphoma, unlike cancers such as breast or colorectal cancer. The most useful advice is to pay attention to persistent swelling of one or more lymph nodes, especially when not linked to infections or inflammation.

How Treatment Decisions Are Made

The choice of the most appropriate treatment always starts with a careful prognostic evaluation based on:

• accurate identification of the lymphoma subtype and its molecular features
• staging, to determine how far the disease has spread
• calculation of prognostic risk scores, when available
• assessment of the patient’s overall health and ability to tolerate treatment

In older patients, a comprehensive geriatric assessment can be particularly helpful in guiding treatment decisions.

Staging

Staging describes how far lymphoma has spread in the body. It is based on imaging tests such as CT and PET scans and follows the Ann Arbor classification:

• Stage I: involvement of a single lymph node area
• Stage II: two or more lymph node areas involved, all on the same side of the diaphragm (either above or below)
• Stage III: lymph nodes involved on both sides of the diaphragm
• Stage IV: widespread disease affecting lymph nodes and other organs (such as liver, spleen, lungs, or bone marrow)

Each stage may be further classified as:

• A: no systemic symptoms
• B: presence of systemic symptoms such as fever, itching, weight loss, or night sweats

Biological Behavior of Lymphoma

Lymphomas are a diverse group of diseases. Some forms grow slowly (indolent lymphomas), while others are more aggressive.

Interestingly, a lymphoma that appears widespread may still behave in a slow and manageable way, while a more localized form can sometimes be biologically aggressive. This is why accurate diagnosis, supported by advanced molecular testing, is essential to define prognosis.

Prognostic Indices

To better estimate prognosis, doctors may use specific scoring systems based on clinical and laboratory factors.

The International Prognostic Index (IPI) is commonly used for aggressive large B-cell lymphomas. It considers:

• age over 60
• advanced stage (III or IV)
• elevated LDH levels
• reduced physical functioning (ECOG performance status)
• involvement of more than one extranodal site

The Follicular Lymphoma International Prognostic Index (FLIPI) is used for follicular lymphoma. It includes:

• age over 60
• advanced stage
• involvement of more than four lymph node areas
• low hemoglobin levels
• elevated LDH

The Mantle Cell Lymphoma Prognostic Index (MIPI) is based on age, ECOG performance status, LDH levels, and white blood cell count.